Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
55 /100
HIGH RISK
Score updated Oct 13, 2026

AKTS — Aktis Oncology, Inc. Dilution Risk Tracker

Track AKTS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AKTS — Get alerts when the score changes →

As of October 13, 2026, Aktis Oncology, Inc. (AKTS) has a DilutionWatch DilutionScore of 55/100, rated HIGH dilution risk. Aktis Oncology, Inc. has a market capitalization of $926.76M, 53.45M shares outstanding, 2 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
35
💰 Cash Runway
65
📊 Float Risk
45
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 12%
💰 Capital Raise model 15%
• Under 12 months cash (11mo)
📉 Score Deterioration model 15%
• Score climbed 8 points (worsening)
🔔 Track AKTS — Get forecast alerts →

Market Data

Market Cap$926.76M
Shares Outstanding53.45M
Float28.15M
Cash$82.49M
Debt$11.58M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore55/100DilutionWatch score record
Shares Outstanding53.45MVerified float table or market cache
Public Float28.15MVerified float table or market cache
Market Cap$926.76MMarket data cache
Cash Runway11.0 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 3 2, 4 3, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

2 institutional holders · 285.9K shares
#1 BARCLAYS PLC 258.1K shares
#2 Kohmann Bosshard Financial Services, LLC 27.8K shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.72M
Days to Cover7.3
% of Float16.8%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-08-13
3 FORM3 2026-04-16
4 INSIDER TRANSACTION 2026-04-16
3 FORM3 2026-01-15
4 INSIDER TRANSACTION 2026-01-14
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual AKTS Dilution Snapshot

Aktis Oncology, Inc. (AKTS) has a DilutionScore of 55/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

AKTS's DilutionScore is currently 55/100 (High risk), with 2 score changes tracked over 89 days. The score improved from 47/100 (Medium risk).

Period Score Risk Level Duration
Oct 13, 202655/100HIGH1 day
Oct 10 – Oct 12, 202647/100MEDIUM3 days
Jul 16 – Oct 09, 202643/100MEDIUM85 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

AKTS shares outstanding have increased 0.0% from 53.40M (Apr 2026) to 53.40M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 19, 202653.40M28.15M▲ 21.32%
May 18, 202653.40M23.20M▼ 11.99%
Apr 20, 202653.40M26.36M▼ 0.10%
Apr 07, 202653.40M26.39M▲ 6.09%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track AKTS Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment AKTS files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking AKTS — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for AKTS
AKTS FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.